🏥 Health & Medicine
Madrigal Pharmaceuticals
(MDGL ↗)
Madrigal makes Rezdiffra — the first and only drug approved for MASH, a serious fatty-liver disease that affects millions of people and had no approved treatment until 2024. Revenue is exploding. It's still losing money, but the loss is shrinking fast. The whole story is a race: scale the first-mover before bigger rivals arrive.
Updated · Q1 2026 · March 2026
$1.1B / yr revenue · public since 2016
↻ The read keeps updating
You're reading the 6 opening chapters. After that, every time Madrigal files a new report, the chapters get updated here.